A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma

被引：58

作者：

Bedikian, Agop Y. ^{[1
]}

Papadopoulos, Nicholas E.

Kim, Kevin B.

Hwu, Wen-Jen

Homsi, Jade

Glass, Michelle R.

Cain, Suzanne

Rudewicz, Patrick ^{[2
]}

Vernillet, Laurent ^{[2
]}

Hwu, Patrick

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Unit 430, Houston, TX 77030 USA

[2] Genentech Inc, San Francisco, CA 94080 USA

来源：

CANCER INVESTIGATION | 2009年 / 27卷 / 07期

关键词：

Temozolomide; INO-1001; PARP inhibitor; Pharmacokinetics; Melanoma; MISMATCH REPAIR-DEFICIENT; ANTITUMOR-ACTIVITY; POLY(ADP-RIBOSE); INHIBITOR; GLIOMA; RESISTANCE; INCREASES; CHEMOPOTENTIATION; ALKYLTRANSFERASE; CYTOTOXICITY;

D O I：

10.1080/07357900802709159

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

INO-1001 is a PARP-1 inhibitor that interrupts the repair process of N-methylpurines generated by temozolomide. We evaluated the pharmacokinetics of INO-1001 and determined its safety when used with temozolomide at 200 mg/m2/day x 5 days every 4 weeks. We enrolled 12 adult patients, in cohorts of 3-6 patients, into the study. INO-1001 at doses of 100, 200 and 400 mg was given intravenous for 1 hr q 12 hr for 10 doses. INO-1001 had a moderate clearance, volume of distribution and a relatively short terminal half-life. Myelosuppression and elevation of liver transaminases were dose-limiting toxicities (DLTs) of INO-1001 at 400 mg.

引用

页码：756 / 763

页数：8

共 27 条

[1]

Anderson C M, 1995, Oncology (Williston Park), V9, P1149

[2] POTENTIATION OF TEMOZOLOMIDE-INDUCED CYTOTOXICITY - A COMPARATIVE-STUDY OF THE BIOLOGICAL EFFECTS OF POLY(ADP-RIBOSE) POLYMERASE INHIBITORS [J].

BOULTON, S ;

PEMBERTON, LC ;

PORTEOUS, JK ;

CURTIN, NJ ;

GRIFFIN, RJ ;

GOLDING, BT ;

DURKACZ, BW .

BRITISH JOURNAL OF CANCER, 1995, 72 (04) :849-856

[3] Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064 [J].

Bowman, KJ ;

White, A ;

Golding, BT ;

Griffin, RJ ;

Curtin, NJ .

BRITISH JOURNAL OF CANCER, 1998, 78 (10) :1269-1277

[4] Radio sensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase [J].

Brock, WA ;

Milas, L ;

Bergh, S ;

Lo, R ;

Szabó, C ;

Mason, KA .

CANCER LETTERS, 2004, 205 (02) :155-160

[5]

Calabrese CR, 2003, CLIN CANCER RES, V9, P2711

[6] Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft [J].

Cheng, CL ;

Johnson, SP ;

Keir, ST ;

Quinn, JA ;

Ali-Osman, F ;

Szabo, C ;

Li, HS ;

Salzman, AL ;

Dolan, ME ;

Modrich, P ;

Bigner, DD ;

Friedman, HS .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (09) :1364-1368

[7] AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study [J].

Fong, P. C. ;

Boss, D. S. ;

Carden, C. P. ;

Roelvink, M. ;

De Greve, J. ;

Gourley, C. M. ;

Carmichael, J. ;

De Bono, J. S. ;

Schellens, J. H. ;

Kaye, S. B. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[8]

FRIEDMAN HS, 1995, CANCER RES, V55, P2853

[9] Cancer statistics, 2007 [J].

Jemal, Ahmedin ;

Siegel, Rebecca ;

Ward, Elizabeth ;

Murray, Taylor ;

Xu, Jiaquan ;

Thun, Michael J. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2007, 57 (01) :43-66

[10]

KINDERS RJ, AACR INT C MOL DIAGN

← 1 2 3 →